Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adimab Discovers Sustainable Profitability Through GSK, Biogen Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

The antibody engineering company Adimab LLC has signed two non-exclusive deals that should put the small biotech firmly in the black. The deals with GSK and Biogen, announced July 26, are Adimab’s first in which it transfers its technology for broad use by partners.


Related Content

Private Adimab Breaks $1 Billion Valuation, Offers VCs Liquidity Through $100 Million Secondary
Adimab Inside: Polaris, Orbimed Back Antibody Attack On Novel Alzheimer’s Biology
Deals Of The Week’s Takeaway From PSA: Optimism With Aches
Deals Of The Week: Bristol And Others May Be Eyeing A Bid For Shire
Deals Of The Week: Tellingly, Teva And Lonza Part Ways
Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts